Earnings Call for Q3FY22 of Piramal Enterprises Ltd
Conference Call with Piramal Enterprises Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.10-02-2022
10-02-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Change in Directorate
Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Independent Director10-02-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Report Of The Auditors On Financial Results For The Quarter And Nine Months Ended 31St December, 2021
In continuation to our financial results for the quarter and nine months ended 31st December, 2021 filed with the stock exchanges after the Board Meeting held today, please find attached independent auditor's reports on these financial results with Unique Document Identification Number. This is also available on the Company''s website at www.piramal.com10-02-2022
Piramal Enterprises Q3 profit up 11% at Rs 888 crore
The company had posted a net profit of Rs 799 crore for the same period last fiscal year.10-02-2022
Q3FY22 Quarterly Result Announced for Piramal Enterprises Ltd.
Piramal Enterprises declares Q3FY22 result: Resilient performance in 9M FY22 despite COVID-19; Normalized Net Profit* at INR 1,978 Cr. Overall loan book grew +31% YoY to ~INR 60,600 Cr; retail AUM grew 4x YoY to INR 21,544 Cr. Pharma business delivered 15% revenue growth YoY and 22% EBITDA margins for Q3 FY22. Expect to complete the demerger in Q3 FY23, subject to various requisite approvals. Retail loan disbursements up 386% YoY in Q3 FY22 to INR 739 Cr. Reduction in cost of borrowings, -180 bps YoY Significant progress on integration of DHFL: Retained 3,000+ employees from DHFL New loan origination restarted at most DHFL branches as of December, 2021 Hiring trend to continue in FY23 as company expands retail operations pan-India, 2,000 offers rolled-out in the past 3 months Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, “Q3 performance reflects the growth across both financial services and pharmaceuticals businesses. The acquisition of DHFL has been value accretive and has enabled us to achieve significant growth. It has materially given a further impetus to our business ambitions and targets. The capacity building in talent and technology, together with a robust business expansion plan gives us the confidence to create a sustainable and profitable retail franchise in coming years. In pharma, we have grown well, despite the logistical and supply chain constraints induced by the pandemic. We made further investments for expanding capacity in niche capabilities. Each of our pharma businesses have a compelling plan for their growth and profitability improvement in coming years. Further, our initiative to create two distinct sector focused entities is progressing well and we expect to complete the demerger in Q3 FY23, subject to various requisite approvals.” Result PDF10-02-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Board Meeting Outcome for Outcome Of Board Meeting
1. The Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31st December, 2021 in terms of Regulation 33 of the Listing Regulations. 2. Cancellation of the unsubscribed portion of the issued capital representing 5,75,372 equity shares of ?2 each aggregating to ?1,150,744/-, which was reserved in favour of the Compulsorily Convertible Debentures holders under rights issue of the Company vide its Letter of Offer dated 1st February, 2018. Consequently, the issued share capital stands at ?477,376,546/- consisting of 238,688,273 equity shares of face value of ?2 each fully paid.10-02-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Outcome Of Board Meeting
1. The Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31st December, 2021 in terms of Regulation 33 of the Listing Regulations. 2. Cancellation of the unsubscribed portion of the issued capital representing 5,75,372 equity shares of Rs. 2 each aggregating to Rs. 1,150,744/-, which was reserved in favour of the Compulsorily Convertible Debentures holders under rights issue of the Company vide its Letter of Offer dated 1st February, 2018. Consequently, the issued share capital stands at Rs. 477,376,546/- consisting of 238,688,273 equity shares of face value of Rs. 2 each fully paid.10-02-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Conference Call with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201507-02-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Board Meeting Intimation for Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
PIRAMAL ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Thursday, 11th November, 2021, inter alia to consider the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September, 2021. In this regard, we write to inform you that the 'Trading Window' for dealing in the securities of the Company has been closed from Friday, 1st October, 2021 and will remain closed till Saturday, 13th November, 2021 (both days inclusive). Further, as per Regulation 47 of the Listing Regulations, the Company shall be publishing only Consolidated results in the newspapers. However, we shall be filing both Standalone and Consolidated results with the Stock Exchange.03-02-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 201528-01-2022